Company intelligence / Profile preview
Glycyx
San Francisco, California, United Statesglycyx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Glycyx’s lead candidate, axelopran, is a peripherally restricted opioid antagonist designed to reverse opioid-induced immunosuppression without compromising pain relief. Preclinical and early clinical data show robust safety and efficacy in restoring immune function and enabling T-cell infiltration into tumors when used with immune checkpoint inhibitors. The company has completed CMC work and built clinical supply through Phase 3.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeripherally restricted opioid antagonist
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships are publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Glycyx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycyx.